Replies to post #241090 on Biotech Values

[DewDiligence]

GH—“Shield” liquid biopsy for colorectal cancer is now available as a “homebrew” lab test (i.e. sans FDA approval):

https://finance.yahoo.com/news/guardant-health-announces-shield-blood-120500175.html

Although GH says Shield is as good as EXAS’ Cologuard and MYNZ’s ColoAlert, I find it hard to believe that a blood test can be as sensitive for CRC (and precancerous lesions) as a stool-based test.

In any event, it will take a few years until Shield can both obtain FDA approval and reimbursement.

[DewDiligence]

MYNZ ColoAlert data—too good to be true?

https://www.globenewswire.com/news-release/2023/10/18/2762319/0/en/Mainz-Biomed-Presents-Groundbreaking-Results-of-ColoFuture-Study.html

Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma [pre-cancerous polyps] sensitivity of 80%

MYNZ’s ColoAlert stool-sample diagnostic for CRC, which is similar to EXAS’ Cologuard, is on the market in Europe and certain other countries but is not yet approved in the US.

MYNZ has an enterprise value of only ~$35M, a minuscule fraction of EXAS’ EV.